SPC 4955

Drug Profile

SPC 4955

Alternative Names: SPC-4955

Latest Information Update: 22 Mar 2016

Price : $50

At a glance

  • Originator Santaris Pharma
  • Developer Roche
  • Class Antihyperlipidaemics; Antisense oligonucleotides
  • Mechanism of Action Antisense RNA inhibitors; Apolipoprotein B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hypercholesterolaemia

Most Recent Events

  • 21 Nov 2011 Santaris Pharma completes a Phase-I trial in healthy volunteers in Germany (NCT01365663)
  • 11 May 2011 Phase-I clinical trials in Hypercholesterolaemia (in volunteers) in Germany (SC)
  • 31 Dec 2007 Preclinical trials in Hypercholesterolaemia in Denmark (parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top